Edris Badreddin's Form 4 filing
Edgewise Therapeutics, Inc. (EWTX) · filed Jan 23, 2026
- Accession no.
- 0001786966-26-000001
- Filed
- Jan 23, 2026, 1:34 PM ET
- Trade date
- Jan 21, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 10 non-derivative transactions and 5 derivative transactions. Open-market sales total $3.40M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Edris BadreddinCIK 0001786966 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 21, 2026 | Common Stock | MOption exerciseAcquired | +13,690 | $0.39 | +$5,339.1 | 33,510 | Direct | |
| Jan 21, 2026 | Common Stock | MOption exerciseAcquired | +17,236 | $0.64 | +$11,031.04 | 50,746 | Direct | |
| Jan 21, 2026 | Common Stock | MOption exerciseAcquired | +10,463 | $1.93 | +$20,193.59 | 61,209 | Direct | |
| Jan 21, 2026 | Common Stock | MOption exerciseAcquired | +66,477 | $1.93 | +$128,300.61 | 127,686 | Direct | |
| Jan 21, 2026 | Common Stock | MOption exerciseAcquired | +7,605 | $0.71 | +$5,399.55 | 135,291 | Direct | |
| Jan 21, 2026 | Common Stock | SSaleDisposed | −13,690 | $29.44F2 | −$403,033.6 | 121,601 | Direct | |
| Jan 21, 2026 | Common Stock | SSaleDisposed | −17,236 | $29.44F2 | −$507,427.84 | 104,365 | Direct | |
| Jan 21, 2026 | Common Stock | SSaleDisposed | −7,605 | $29.44F2 | −$223,891.2 | 96,760 | Direct | |
| Jan 21, 2026 | Common Stock | SSaleDisposed | −10,463 | $29.44F2 | −$308,030.72 | 86,297 | Direct | |
| Jan 21, 2026 | Common Stock | SSaleDisposed | −66,477 | $29.44F2 | −$1,957,082.88 | 19,820 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 21, 2026 | Common Stock | MOption exerciseDisposed | −10,463 | $0.00 | $0 | 0 | Direct | |
| Jan 21, 2026 | Common Stock | MOption exerciseDisposed | −66,477 | $0.00 | $0 | 0 | Direct | |
| Jan 21, 2026 | Common Stock | MOption exerciseDisposed | −7,605 | $0.00 | $0 | 0 | Direct | |
| Jan 21, 2026 | Common Stock | MOption exerciseDisposed | −17,236 | $0.00 | $0 | 0 | Direct | |
| Jan 21, 2026 | Common Stock | MOption exerciseDisposed | −13,690 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 5 transactions in Table I.